SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy ...
The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolment Futility analysis remains on track for the first quarter of CY2026 and completion ...
A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation. This is an ASCO Meeting Abstract from the ...
SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE)-- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or "the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for ...
Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved ...
SYDNEY, AUSTRALIA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, ...
A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in ...
Tacti-con is a fan convention that focuses on games — from old-fashioned board games to the vast universe of the gaming cyberworld. And for those who tired of sitting around tables and staring at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results